Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

Bibliography

• LOWENBERG B, DOWNING JR, BURNETT A: Acute myeloid leukemia. N Engl. J Med. (1999) 341:1051–1062.
   PubMed Web of Science ®Google Scholar
• •An extensive review of the diagnosis and treatment of acute myeloid leukaemia.
   Google Scholar
• BRINCKER H: Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat. Rep. (1985) 69:5–11.
   PubMedGoogle Scholar
• ROWE JM: What is the best induction regime for acute myelogenous leukemia? Leukemia (1988) 12:S16–S19.
   Google Scholar
• BISHOP JF: The treatment of adult acute myeloid leukemia. Semi]. Oncol (1997) 24:57–69.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, ESTEY EH, KEATING MA: New chemotherapeutic agents in acute myeloid leukemia. Leukemia (1996) 10:S4–S6.
   PubMed Web of Science ®Google Scholar
• WELBORN JL, KOPECKY KJ, MEYERS FJ et al.: Carboplatin infusion in relapsed and refractory acute myeloid leukemia - a Southwest Oncology Group trial. Leukemia (1995) 9:1126–1129.
   PubMed Web of Science ®Google Scholar
• REES JKH, SWIRSKY D, GRAY R et al: Principal results of the Medical Research Council's 8th acute myeloid leukemia trial. Lancet (1986):1236–1241.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, KANTARJIAN H, SMITH TL et al: Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J. Clin. Oncol (1989) 7:1071–1080.
   PubMed Web of Science ®Google Scholar
• THALHANIMER F, GEISSLER K, JAGER U et al.: Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann. Hematol (1996) 72:216–222.
   PubMed Web of Science ®Google Scholar
• HIDDEMANN W MARTIN WR, SAUERLAND C et al: Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD9) in 150 patients with relapse after standardized first line therapy. Leukemia (1990) 4:184–188.
   PubMed Web of Science ®Google Scholar
• DAVIS CL, ROHATINER AZS, LIM J et al.: The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br j. Haematol (1993) 83:404–411.
   PubMed Web of Science ®Google Scholar
• ANGELOV L, BRANDWEIN JM, BAKER MA et al.: A: Results of therapy for acute myeloid leukemia in first relapse. Leuk. Lymphoma (1991) 6:15–24.
   PubMed Web of Science ®Google Scholar
• ARCHIMBAUD E, LEBLOND V, FENAUX P etal.: Time sequential chemotherapy for advanced acute myeloid leukemia. Hematol Cell Ther. (1996) 38:161–167.
   Google Scholar
• VIGNETTI M, ORSINI E, PETTI MC et al.: Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann. Oncol (1996) 7:933–938.
   PubMed Web of Science ®Google Scholar
• CARELLA ANI, CARLIER P, PUNGOLINO E et al: Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia (1993) 7:196–199.
   PubMed Web of Science ®Google Scholar
• KERN W, AUL C, MASCHMEYER G et al:Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia (1998) 12:1049–1055.
   PubMed Web of Science ®Google Scholar
• VOGLER WR, MCCARLEY DL, STAGG M etal.: A Phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia (1994) 8:1847–1853.
   Google Scholar
• THOMAS X, FENAUX P, DOMBRET H et al.: Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMAS I trial). Leukemia (1999) 13:1214–1220.
   PubMed Web of Science ®Google Scholar
• OHNO R, NAOE T, KARAMARU A et al: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood (1994) 83:2086–2092.
   PubMed Web of Science ®Google Scholar
• STOCKERL-GOLDSTEIN KE, BLUME KG: Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Hematopoietic Cell Transplantation. Forman SJ, Blume KG, Thomas ED (Eds.). Vol 2. Blackwell Science, MA, USA (1999):823–834.
   Google Scholar
• GRIFFIN JD, LINCH D, SABBATH K et al.: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res. (1984) 8:521–534.
   PubMed Web of Science ®Google Scholar
• LEGRAND 0, PERROT J-Y, BAUDARD M et al: The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood (2000) 96:870–877.
   PubMed Web of Science ®Google Scholar
• DINNDORF PA, ANDREWS RG, BENJAMIN D et al: Expression of normal myeloid-associated antigens by acute leukemia cells. Blood (1986) 67:1048–1053.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN ID, SINGER JW, SMITH FOet al.: Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood (1992) 79:1811–1816.
   Google Scholar
• SCHEINBERG DA, LOVETT D, DIVGI CR et al: A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. j. Clin. Oncol (1991) 9:478–490.
   PubMed Web of Science ®Google Scholar
• •Description of the first trial of unconjugated anti-CD33 antibody for ANIL.
   Google Scholar
• CARON PC, DUMONT L, SCHEINBERG DA: Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin. Cancer Res. (1998) 4:1421–1428.
   PubMed Web of Science ®Google Scholar
• •A report describing supersaturating doses of unconjugated anti-CD33 antibody for advanced leukaemia.
   Google Scholar
• FELDMAN E, KALAYCIO M, SCHULMAN P et al: Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): preliminary report of a Phase II study. Proc. Am. Soc. Clin. Oncol (1999) 18:4a.
   Google Scholar
• CLIFT RA, BUCKNER CD, APPELBAUM FR etal.: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 76:1867–1871.
   Google Scholar
• CLIFT RA, BUCKNER CD, APPELBAUM FR etal.: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood (1991) 77:1660–1665.
   Google Scholar
• SIEVERS EL, APPELBAUM FR, SPIELBERGER RT et al: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 93:3678–3684.
   PubMed Web of Science ®Google Scholar
• ••A report describing the initial Phase Ievaluation of gemtuzumab ozogamicin for patients with advanced AML.
   Google Scholar
• ZEIN N, PONCIN M, NILAKANTAN R et al.: Calicheamicin yjI and DNA: molecular recognition process responsible for site-specificity. Science (1989) 244:697–699.
   PubMed Web of Science ®Google Scholar
• HAMANN PR, HINMAN LM, HOLLANDER IJ et al: Anti-CD33 calicheamicin hybrid conjugates for the treatment of acute myelogenous leukemia. Proc. Am. Assoc. Cancer Res (1996) 37:471.
   Google Scholar
• WANG CE LIM H-K, HULTIN T et al: Characterization of in vitro metabolism of two postulated hydrolytic products of CMA-676, NAc-y-calicheamicin DMH and NAc-y-calicheamicin DMH AcBUT in human liver microsomes and cytosol and NAc-y-calicheamicin DMH in HL-60 promyelocytic leukemia cells. ISSX Proc. (1999) 15:(Abstract 220).
   Google Scholar
• DOWELL JA, BERGER MS, KING SP, KORTH-BRADLEY J, LIU H: The pharmacokinetics of gemtuzumab ozogamicin: an antibody-targeted chemotherapy agent for relapsed acute myeloid leukemia. Blood (2000) 96:120a.
   Web of Science ®Google Scholar
• •An abstract describing pharmacoltinetic results with gemtuzumab ozogamicin.
   Google Scholar
• DOWELL JA, KING SP, LIU H, BERGER MS, KORTH-BRADLEY JM: A population pharmacokinetic analysis of gemtuzumab ozogamicin: a new antibody chemotherapeutic agent. Clin. Pharm. Ther. (2000) 67:138. (Abstract PII–93).
   Google Scholar
• KORTH-BRADLEY J, DOWELL JA, BERGER MS, LIU H, KING SP: Assessment of the possible influence of patient demographics on the pharmacokinetics of a new antibody-chemotherapy agent for relapsed acute myelogenous leukemia. Pharmacotherapy (1999) 19:1217 (Abstract 157).
   Google Scholar
• SIEVERS EL, ARCECI R, FRANKLIN J et al.: Preliminary report of an ascending dose study of gemtuzumab ozogamicin (Mylotarg, CMA-676) in pediatric patients with acute myeloid leukemia. Blood (2000) 96:2176.
   Google Scholar
• •An abstract describing the interim results of the pediatric dose escalation study of gemtuzumab ozogamicin.
   Google Scholar
• SIEVERS EL, LARSON RA, STADTMAUER EA etal.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. j Cliii. Oricol (2001) 19:3244–3254.
   Google Scholar
• ••Describes pivotal Phase II efficacy andsafety results on gemtuzumab ozogamicin in the treatment of patients with AML in first relapse.
   Google Scholar
• MALLLICK R: A decision analysis of expected cost savings associated with outpatient administration of ozogamicin (Mylotarg, CMA-676) in patients with first relapse of acute myeloid leukemia. Proc. Am. Soc. Hematol. (2000) 439a. (Abstract).
   Google Scholar
• •An abstract describing a retrospective cost analysis associated with the clinical use of gemtuzumab ozogamicin.
   Google Scholar
• WINKLER U, JENSEN, M, MANZKE 0 etal.: A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood (1999) 94:2217–2224.
   Google Scholar